ARS Pharmaceuticals, Inc. (SPRY) › Shareholders' EquityARS Pharmaceuticals, Inc. (SPRY) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$58.78M2020: -$14.05M2021: -$31.27M2022: $272.89M2023: $230.76M2024: $256.80M2025: $114.26M$114.26M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$114.26M-55.5%2024$256.80M+11.3%2023$230.76M-15.4%2022$272.89M+972.7%2021-$31.27M-122.5%2020-$14.05M+76.1%2019-$58.78M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share